Collaborations internationales : 2 papiers font l'objet d'un highlight commun dans Nature Reviews
The NLRP3 inflammasome fuels numerous common multifactorial diseases including arthritis, diabetes, atherosclerosis and Alzheimer’s disease, as well as, age-associated functional decline, by promoting deleterious inflammation.
Development of NLRP3 inhibitors has high therapeutic potentials but faces selectivity, limited efficacy and toxicity challenges for translation into clinic. The NLRP3 Team (CIRI, Lyon) recently participated in two collaborative studies (with BioAge Labs Inc. (CA, USA), R. Coll (Queen’s University, Belfast) and M. Geyer (University of Bonn), and R. Karki (Seoul National University)) reporting the identification of novel selective NLRP3 inhibitors, highlighted in Nature Reviews drug discovery.
For further information, links to the papers and highlight:
- https://www.nature.com/articles/d41573-025-00156-1
- https://doi.org/10.1084/jem.20242403
- https://doi.org/10.1016/j.chembiol.2025.08.006
